Related Experiment Video

Updated: Jan 17, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its

Dongchao Xu1, Yuanling Zhu2, Wuhan Ye3

  • 1Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou 310006, China; Hangzhou Institute of Digestive Diseases, Hangzhou 310000, China; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310006, China; Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou 310006, China.

Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|September 20, 2025
PubMed
Abstract

Insights

Daurisoline (DAU) inhibits pancreatic cancer progression by targeting the PPARα and JAK2/STAT3 pathway. It suppresses cell growth and invasion by preventing PPARα ubiquitination, offering a new therapeutic strategy for pancreatic cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Pancreatic cancer (PC) has a high mortality rate with limited treatment options.
  • Daurisoline (DAU), a natural alkaloid, shows antitumor potential, but its mechanism is unclear.

Purpose of the Study:

  • To evaluate Daurisoline's (DAU) inhibitory effects on pancreatic cancer (PC).
  • To elucidate the mechanisms underlying DAU's action, focusing on the PPARα and JAK2/STAT3 pathway.

Main Methods:

  • Cell proliferation, migration, invasion, cell cycle, and apoptosis assays were performed.
  • Bioinformatics analysis identified molecular targets.
  • PPARα lentiviral transduction and STAT3 activator treatments investigated pathway roles.
  • Coimmunoprecipitation assays examined DAU's effect on PPARα ubiquitination.

Main Results:

  • DAU suppressed PC cell proliferation, migration, and invasion in a dose- and time-dependent manner.
  • DAU induced G1 cell cycle arrest and apoptosis.
  • DAU increased PPARα expression, suppressed JAK2/STAT3 signaling, and inhibited PPARα ubiquitination by blocking Trim63 interaction.

Conclusions:

  • DAU inhibits pancreatic cancer progression by preventing PPARα ubiquitination and suppressing the JAK2/STAT3 pathway.
  • DAU presents a novel therapeutic strategy for pancreatic cancer via ubiquitination pathway modulation.
Keywords:
DaurisolineJAK2/STAT3 signaling pathwayPPARαPancreatic ductal adenocarcinomaUbiquitination

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.4K
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

29.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K